Annexon Inc Ordinary Shares ANNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.89
- Day Range
- $5.68–6.16
- 52-Week Range
- $2.03–7.18
- Bid/Ask
- $5.83 / $6.00
- Shares Outstanding
- 163.84M
- Market Cap
- $950.29M
- Volume/Avg
- 3M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 93
- Website
- https://www.annexonbio.com
Valuation
|
Metric
|
ANNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.61 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ANNX
|
|---|---|
Quick Ratio | 6.26 |
Current Ratio | 6.35 |
Interest Coverage | — |
Quick Ratio
ANNX
Profitability
|
Metric
|
ANNX
|
|---|---|
Return on Assets (Normalized) | −67.67% |
Return on Equity (Normalized) | −88.68% |
Return on Invested Capital (Normalized) | −82.06% |
Return on Assets
ANNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<@&Rkcw | LOCK|dkm@ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%S%XPb | LOCK|gK#@ | $71B | |||
| argenx SE ADR
ARGX
| LOCK|#&#$%Gx | LOCK|&m | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|MZnx!r? | LOCK|l^G | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&d^V#@ | LOCK|Yxs! | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|h!WjyhX | LOCK|KCJq@ | $26B | |||
| Moderna Inc
MRNA
| LOCK|M^%S^p | LOCK|tX | $25B | |||
| Incyte Corp
INCY
| LOCK|@qhSr^ | LOCK|Dz# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!nM?RS | LOCK|$%Q | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Nd&v<V& | LOCK|d!% | $16B |
United States